Methylfolate Granule Stability via Segmentation and Intermediary
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Methylfolate is unstable in various environmental conditions, such as changes in pH, temperature, and exposure to light, making it challenging to integrate into pharmaceutical and nutraceutical compositions without degrading, especially when combined with other active ingredients like carnitine derivatives and vitamins, which affects its stability and efficacy in treating disorders like depression and neuropathies.
Innovation Solution
A stable composition comprising granules of calcium L-methylfolate in crystalline form combined with acetyl L-carnitine salt and pharmaceutically acceptable excipients, characterized by a specific ratio of methylfolate to antioxidant, is developed, ensuring stability for at least 6 months without degradation, even in the presence of hydrated ingredients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If methylfolate is combined with other active ingredients like carnitine derivatives and vitamins in pharmaceutical compositions, then the therapeutic efficacy for treating depression and neuropathies is improved, but the stability of methylfolate deteriorates due to degradation from environmental conditions and interactions with other ingredients
Solution Approach 1:
The patent divides the pharmaceutical composition into separate granules: one granule containing methylfolate and another granule containing carnitine derivative and vitamins. This segmentation prevents direct interaction between methylfolate and potentially degrading ingredients while allowing both to be administered together for synergistic therapeutic effect.
Solution Approach 2:
The patent uses specific excipients as intermediaries in the granule formulation. These excipients act as protective mediators that stabilize methylfolate within the granule structure, shielding it from environmental degradation factors (pH changes, temperature, light) and preventing harmful interactions with other active ingredients while maintaining bioavailability.
2Ease of operation
If methylfolate is formulated in conventional pharmaceutical forms, then ease of administration is improved, but manufacturing complexity increases due to the need for special stabilization measures against degradation
Solution Approach 1:
By segmenting the formulation into separate granules with distinct functions (one for methylfolate, one for other ingredients), the patent simplifies the manufacturing process. Each granule can be produced and stabilized independently using standard pharmaceutical techniques, avoiding the need for complex integrated stabilization systems required in conventional single-formula approaches.
Data Source
AI summary
The present invention describes a pharmaceutical and/or nutritional composition comprising methylfolate in the form of granules, together with a carnitine derivative salt, pharmaceutically acceptable excipients, and optionally other pharmaceutical or nutraceutical active ingredients. The composition is useful for oral administration. The invention also relates to the process for obtaining the composition comprising methylfolate in the form of granules and the use thereof for the treatment of disorders associated with a reduction of methylfolate, wherein methylfolate is useful.